Citius Oncology shares surge 24.24% after-hours on strong LYMPHIR commercial adoption and clinical progress.

Citius Oncology surged 24.24% in after-hours trading following a commercial update on LYMPHIR, highlighting strong institutional adoption, broad payer coverage, and early clinical progress. The company reported that 83% of target accounts have added LYMPHIR to formularies, with repeat orders and no reimbursement barriers. Early clinical results, including an 86% response rate in a Phase 1 trial before CAR-T therapy, and positive data from studies combining LYMPHIR with pembrolizumab, further reinforced the drug’s potential. These developments signal robust commercial execution and expanding clinical validation, boosting investor confidence in the drug’s market integration and long-term growth prospects.